Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Expression of miR-18a and miR-210 in Normal Breast Tissue as Candidate Biomarkers of Breast Cancer Risk.

Shidfar A, Costa FF, Scholtens D, Bischof JM, Sullivan ME, Ivancic DZ, Vanin EF, Soares MB, Wang J, Khan SA.

Cancer Prev Res (Phila). 2017 Jan;10(1):89-97. doi: 10.1158/1940-6207.CAPR-16-0177. Epub 2016 Oct 27.

2.

Extensive miRNA expression analysis in craniopharyngiomas.

Samis J, Vanin EF, Sredni ST, de Bonaldo Mde F, Costa FF, Tomita T, Habiby R, Zimmerman D, Soares MB.

Childs Nerv Syst. 2016 Sep;32(9):1617-24. doi: 10.1007/s00381-016-3131-1. Epub 2016 Jun 7.

PMID:
27272948
3.

Human rhinovirus infection causes different DNA methylation changes in nasal epithelial cells from healthy and asthmatic subjects.

McErlean P, Favoreto S Jr, Costa FF, Shen J, Quraishi J, Biyasheva A, Cooper JJ, Scholtens DM, Vanin EF, de Bonaldo MF, Xie H, Soares MB, Avila PC.

BMC Med Genomics. 2014 Jun 19;7:37. doi: 10.1186/1755-8794-7-37.

4.

Onset of rosette formation during spontaneous neural differentiation of hESC and hiPSC colonies.

Malchenko S, Xie J, de Fatima Bonaldo M, Vanin EF, Bhattacharyya BJ, Belmadani A, Xi G, Galat V, Goossens W, Seftor RE, Tomita T, Crispino J, Miller RJ, Bohn MC, Hendrix MJ, Soares MB.

Gene. 2014 Jan 25;534(2):400-7. doi: 10.1016/j.gene.2013.07.101. Epub 2013 Aug 15.

5.

Convection-enhanced delivery of nanodiamond drug delivery platforms for intracranial tumor treatment.

Xi G, Robinson E, Mania-Farnell B, Vanin EF, Shim KW, Takao T, Allender EV, Mayanil CS, Soares MB, Ho D, Tomita T.

Nanomedicine. 2014 Feb;10(2):381-91. doi: 10.1016/j.nano.2013.07.013. Epub 2013 Aug 3.

PMID:
23916888
6.

Differentially expressed miRNAs in retinoblastoma.

Martin J, Bryar P, Mets M, Weinstein J, Jones A, Martin A, Vanin EF, Scholtens D, Costa FF, Soares MB, Laurie NA.

Gene. 2013 Jan 10;512(2):294-9. doi: 10.1016/j.gene.2012.09.129. Epub 2012 Oct 26.

PMID:
23103829
7.

Identification of microRNAs as potential prognostic markers in ependymoma.

Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, Rajaram V, Bonaldo Mde F, Wang D, Goldman S, Tomita T, Soares MB.

PLoS One. 2011;6(10):e25114. doi: 10.1371/journal.pone.0025114. Epub 2011 Oct 28.

8.

Identification of Differentially Expressed MicroRNAs in Osteosarcoma.

Lulla RR, Costa FF, Bischof JM, Chou PM, de F Bonaldo M, Vanin EF, Soares MB.

Sarcoma. 2011;2011:732690. doi: 10.1155/2011/732690. Epub 2011 Jul 18.

9.

Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors.

Hamm CA, Stevens JW, Xie H, Vanin EF, Morcuende JA, Abdulkawy H, Seftor EA, Sredni ST, Bischof JM, Wang D, Malchenko S, Bonaldo Mde F, Casavant TL, Hendrix MJ, Soares MB.

BMC Cancer. 2010 Sep 1;10:471. doi: 10.1186/1471-2407-10-471.

10.

Cancer hallmarks in induced pluripotent cells: new insights.

Malchenko S, Galat V, Seftor EA, Vanin EF, Costa FF, Seftor RE, Soares MB, Hendrix MJ.

J Cell Physiol. 2010 Nov;225(2):390-3. doi: 10.1002/jcp.22280.

11.

Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity.

Hamm CA, Xie H, Costa FF, Vanin EF, Seftor EA, Sredni ST, Bischof J, Wang D, Bonaldo MF, Hendrix MJ, Soares MB.

PLoS One. 2009 Dec 17;4(12):e8340. doi: 10.1371/journal.pone.0008340.

12.

Longitudinal assessment of regional directed delivery in a rodent malignant glioma model.

Kondo A, Goldman S, Lulla RR, Mania-Farnell B, Vanin EF, Sredni ST, Rajaram V, Soares MB, Tomita T.

J Neurosurg Pediatr. 2009 Dec;4(6):592-8. doi: 10.3171/2009.7.PEDS09186.

PMID:
19951051
13.

An experimental brainstem tumor model using in vivo bioluminescence imaging in rat.

Kondo A, Goldman S, Vanin EF, Sredni ST, Rajaram V, Soares MB, Tomita T.

Childs Nerv Syst. 2009 May;25(5):527-33. doi: 10.1007/s00381-008-0783-5. Epub 2009 Jan 13.

PMID:
19139905
14.

Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences.

Pule MA, Rousseau A, Vera J, Heslop HE, Brenner MK, Vanin EF.

Cytotherapy. 2008;10(5):526-39. doi: 10.1080/14653240802192636.

15.

An inducible caspase 9 safety switch for T-cell therapy.

Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM.

Blood. 2005 Jun 1;105(11):4247-54. Epub 2005 Feb 22.

17.

Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability.

Davidoff AM, Ng CY, Zhang Y, Streck CJ, Mabry SJ, Barton SH, Baudino T, Zhou J, Kerbel RS, Vanin EF, Nathwani AC.

Mol Ther. 2005 Feb;11(2):300-10.

18.

Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells.

Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D, Piedra PA, Brenner MK, Rooney CM.

Blood. 2004 Oct 15;104(8):2432-40. Epub 2004 Jul 20.

PMID:
15265797
19.

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA.

Nat Biotechnol. 2004 May;22(5):589-94. Epub 2004 Apr 4. Erratum in: Nat Biotechnol. 2004 Dec;22(12):1590. Nat Biotechnol. 2004 Jun;22(6):760.

PMID:
15064769
20.

Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells.

Brenner S, Whiting-Theobald NL, Linton GF, Holmes KL, Anderson-Cohen M, Kelly PF, Vanin EF, Pilon AM, Bodine DM, Horwitz ME, Malech HL.

Blood. 2003 Oct 15;102(8):2789-97. Epub 2003 Jun 26.

PMID:
12829597
21.

Prolonged multilineage clonal hematopoiesis in a rhesus recipient of CD34 positive cells marked with a RD114 pseudotyped oncoretroviral vector.

Kelly PF, Donahue RE, Vandergriff JA, Takatoku M, Bonifacino AC, Agricola BA, Metzger ME, Dunbar CE, Nienhuis AW, Vanin EF.

Blood Cells Mol Dis. 2003 Jan-Feb;30(1):132-43.

PMID:
12667996
22.

Retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 restricts angiogenesis and neuroblastoma growth in mice.

Spurbeck WW, Ng CY, Vanin EF, Davidoff AM.

Cancer Gene Ther. 2003 Mar;10(3):161-7.

PMID:
12637936
23.

The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.

Desmond JC, Mountford JC, Drayson MT, Walker EA, Hewison M, Ride JP, Luong QT, Hayden RE, Vanin EF, Bunce CM.

Cancer Res. 2003 Jan 15;63(2):505-12.

24.

MDM2 does not influence p53-mediated sensitivity to DNA-damaging drugs.

McKenzie PP, McPake CR, Ashford AA, Vanin EF, Harris LC.

Mol Cancer Ther. 2002 Oct;1(12):1097-104.

25.
26.

Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.

Nathwani AC, Davidoff AM, Hanawa H, Hu Y, Hoffer FA, Nikanorov A, Slaughter C, Ng CY, Zhou J, Lozier JN, Mandrell TD, Vanin EF, Nienhuis AW.

Blood. 2002 Sep 1;100(5):1662-9.

PMID:
12176886
27.

The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells.

Jordan CT, Vanin EF, Marini FC.

Curr Gene Ther. 2001 Sep;1(3):257-65. Review.

PMID:
12109141
28.

rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.

Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF.

Cancer Res. 2002 Jun 1;62(11):3077-83.

29.

Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood.

Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P, Vanin EF, Nienhuis AW.

Mol Ther. 2002 Mar;5(3):242-51.

30.

Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice.

Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, Horwitz E, Vanin EF, Nienhuis AW.

Clin Cancer Res. 2001 Sep;7(9):2870-9.

31.

Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model.

Davidoff AM, Leary MA, Ng CY, Spurbeck WW, Frare P, Vanhove M, Nienhuis AW, Vanin EF.

Cancer Gene Ther. 2001 Jul;8(7):537-45.

32.

Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.

Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV.

Cancer Res. 2001 Aug 1;61(15):5810-6.

33.

RD114-pseudotyped oncoretroviral vectors. Biological and physical properties.

Kelly PF, Carrington J, Nathwani A, Vanin EF.

Ann N Y Acad Sci. 2001 Jun;938:262-76; discussion 276-7.

PMID:
11458516
34.

Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia C gene after conditioning with low-dose irradiation.

Kang EM, Hanazano Y, Frare P, Vanin EF, De Witte M, Metzger M, Liu JM, Tisdale JF.

Mol Ther. 2001 Jun;3(6):911-9.

35.

Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.

Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW.

Blood. 2001 Mar 1;97(5):1258-65.

PMID:
11222368
36.
37.
38.

Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development.

Wen R, Wang D, McKay C, Bunting KD, Marine JC, Vanin EF, Zambetti GP, Korsmeyer SJ, Ihle JN, Cleveland JL.

Mol Cell Biol. 2001 Jan;21(2):678-89.

39.

Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy.

Haight AE, Bowman LC, Ng CY, Vanin EF, Davidoff AM.

Med Pediatr Oncol. 2000 Dec;35(6):712-5.

PMID:
11107153
40.

Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo.

Davidoff AM, Leary MA, Ng CY, Vanin EF.

Med Pediatr Oncol. 2000 Dec;35(6):638-40.

PMID:
11107136
42.

Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.

Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ.

Nat Med. 2000 May;6(5):529-35.

PMID:
10802708
44.

Adenovirus-mediated expresssion of the murine ecotropic receptor facilitates transduction of human hematopoietic cells with an ecotropic retroviral vector.

Nathwani AC, Persons DA, Stevenson SC, Frare P, McClelland A, Nienhuis AW, Vanin EF.

Gene Ther. 1999 Aug;6(8):1456-68.

45.

Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12.

Davidoff AM, Kimbrough SA, Ng CY, Shochat SJ, Vanin EF.

J Pediatr Surg. 1999 May;34(5):902-6; discussion 906-7.

PMID:
10359203
46.

High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells.

Marx JC, Allay JA, Persons DA, Nooner SA, Hargrove PW, Kelly PF, Vanin EF, Horwitz EM.

Hum Gene Ther. 1999 May 1;10(7):1163-73.

PMID:
10340548
47.

Enhanced neuroblastoma transduction for an improved antitumor vaccine.

Davidoff AM, Stevenson SC, McClelland A, Shochat SJ, Vanin EF.

J Surg Res. 1999 May 15;83(2):95-9.

PMID:
10329101
48.

Vector development: a major obstacle in human gene therapy.

Jane SM, Cunningham JM, Vanin EF.

Ann Med. 1998 Oct;30(5):413-5. Review.

PMID:
9814826
49.

Targeted integration of a recombinant globin gene adeno-associated viral vector into human chromosome 19.

Bertran J, Yang Y, Hargrove P, Vanin EF, Nienhuis AW.

Ann N Y Acad Sci. 1998 Jun 30;850:163-77.

PMID:
9668538
50.

An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.

Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF.

Blood Cells Mol Dis. 1998 Jun;24(2):167-82.

PMID:
9642098

Supplemental Content

Loading ...
Support Center